From GlobeNewswire: 2024-10-19 08:00:00

Nurix Therapeutics presented encouraging clinical data from the ongoing Phase 1a/1b trial of NX-5948, a BTK degrader, in patients with Waldenstrom’s macroglobulinemia at IWWM-12. Out of 9 evaluable patients, 7 showed objective responses, with deepening responses over time. Safety profile for patients with WM was consistent with overall population. Among 13 WM patients, responses observed regardless of mutation status in MYD88 and CXCR4. NX-5948 demonstrated durability in responses, with two patients on treatment for over a year. Case studies highlighted rapid and deepening response in patients previously treated with BTK inhibitors. Nurix is focused on innovative therapies for cancer and inflammatory diseases and is headquartered in San Francisco, California.



Read more at GlobeNewswire: Nurix Therapeutics Presents Positive Results from the